Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Cameron

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Skinmed|May 23, 2017
Chronic Tender Ulcers on the Calf and Both ForearmsMichael C Cameron, Mitsuya Katayama, Nishit S Patel, et al.
Journal of the American Academy of Dermatology|May 22, 2018
Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associationsMichael C Cameron, Erica Lee, Brian P Hibler, et al.
The Journal of Dermatological Treatment|June 28, 2022
Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of lifeAndrew Blauvelt, Mark Boguniewicz, Patrick M Brunner, et al.
Journal of the American Academy of Dermatology|April 19, 2022
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)Vivian Y Shi, Tina Bhutani, Luz Fonacier, et al.
Journal of the American Academy of Dermatology|May 22, 2018
Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and preventionMichael C Cameron, Erica Lee, Brian P Hibler, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 27, 2021
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy StudiesBrian S Kim, Jonathan I Silverberg, Sonja Ständer, et al.
The Journal of Dermatological Treatment|May 2, 2024
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up studyNina Magnolo, Michael C Cameron, Mona Shahriari, et al.
American Journal of Clinical Dermatology|December 13, 2022
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE TrialSonja Ständer, Shawn G Kwatra, Jonathan I Silverberg, et al.
Dermatology and Therapy|September 11, 2023
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 TrialsSeemal R Desai, Linda Stein Gold, Michael C Cameron, et al.
JAAD International|August 19, 2021
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPAREMelinda J Gooderham, Chia-Yu Chu, Ricardo Rojo, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Skinmed|May 23, 2017
Chronic Tender Ulcers on the Calf and Both ForearmsMichael C Cameron, Mitsuya Katayama, Nishit S Patel, et al.
Journal of the American Academy of Dermatology|May 22, 2018
Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associationsMichael C Cameron, Erica Lee, Brian P Hibler, et al.
The Journal of Dermatological Treatment|June 28, 2022
Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of lifeAndrew Blauvelt, Mark Boguniewicz, Patrick M Brunner, et al.
Journal of the American Academy of Dermatology|April 19, 2022
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)Vivian Y Shi, Tina Bhutani, Luz Fonacier, et al.
Journal of the American Academy of Dermatology|May 22, 2018
Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and preventionMichael C Cameron, Erica Lee, Brian P Hibler, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 27, 2021
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy StudiesBrian S Kim, Jonathan I Silverberg, Sonja Ständer, et al.
The Journal of Dermatological Treatment|May 2, 2024
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up studyNina Magnolo, Michael C Cameron, Mona Shahriari, et al.
American Journal of Clinical Dermatology|December 13, 2022
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE TrialSonja Ständer, Shawn G Kwatra, Jonathan I Silverberg, et al.
Dermatology and Therapy|September 11, 2023
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 TrialsSeemal R Desai, Linda Stein Gold, Michael C Cameron, et al.
JAAD International|August 19, 2021
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPAREMelinda J Gooderham, Chia-Yu Chu, Ricardo Rojo, et al.
Pageof 3